Ipilimumab

Generic Name
Ipilimumab
Brand Names
Yervoy
Drug Type
Biotech
Chemical Formula
-
CAS Number
477202-00-9
Unique Ingredient Identifier
6T8C155666
Background

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication

Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions
Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
First Line Chemotherapy

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

First Posted Date
2014-07-10
Last Posted Date
2017-02-08
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT02186249
Locations
🇺🇸

Medstar Health Research Institute, Baltimore, Maryland, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 61 locations

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

First Posted Date
2014-06-25
Last Posted Date
2020-05-12
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
158
Registration Number
NCT02174172
Locations
🇺🇸

HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States

🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

Yale University, New Haven, Connecticut, United States

and more 6 locations

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-04-15
Last Posted Date
2018-10-29
Lead Sponsor
Duke University
Target Recruit Count
4
Registration Number
NCT02115243
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-04-15
Last Posted Date
2022-11-08
Lead Sponsor
Grupo Español Multidisciplinar de Melanoma
Target Recruit Count
58
Registration Number
NCT02115139
Locations
🇪🇸

H.U. Virgen Macarena, Sevilla, Spain

🇪🇸

Clínica Universidad de Navarra, Pamplona, Spain

🇪🇸

H. Clinic de Barcelona, Barcelona, Spain

and more 9 locations

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-04-14
Last Posted Date
2024-05-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT02113657
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

First Posted Date
2014-03-27
Last Posted Date
2021-05-12
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
4
Registration Number
NCT02097732
Locations
🇺🇸

University of Michigan Hospital, Ann Arbor, Michigan, United States

Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma

First Posted Date
2014-03-21
Last Posted Date
2016-06-09
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
4
Registration Number
NCT02094391
Locations
🇫🇷

Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

First Posted Date
2014-02-27
Last Posted Date
2020-06-05
Lead Sponsor
NewLink Genetics Corporation
Target Recruit Count
132
Registration Number
NCT02073123
Locations
🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

🇺🇸

Penn State Hershey Cancer Institue, Hershey, Pennsylvania, United States

🇺🇸

Augusta University, Augusta, Georgia, United States

and more 3 locations

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.

First Posted Date
2014-02-21
Last Posted Date
2023-03-24
Lead Sponsor
Oslo University Hospital
Target Recruit Count
150
Registration Number
NCT02068196
Locations
🇳🇴

Haukeland University Hospital, Bergen, Norway

🇳🇴

Oslo University Hospital, Oslo, Norway

🇳🇴

Nordland Hospital Bodø, Bodø, Norway

and more 5 locations

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

First Posted Date
2014-02-11
Last Posted Date
2024-11-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
385
Registration Number
NCT02060188
Locations
🇺🇸

Local Institution - 0028, Gilbert, Arizona, United States

🇺🇸

Local Institution - 0004, Los Angeles, California, United States

🇺🇸

Local Institution - 0036, Boston, Massachusetts, United States

and more 29 locations
© Copyright 2024. All Rights Reserved by MedPath